martedì, 21 marzo 2023

Notizie AIOM – anno XIV n. 576

21 marzo 2016 – Health data affidabili migliorano i sistemi sanitari: OMS lancia partnership internazionale che supporta i Paesi in via di sviluppo

21 marzo 2016 – Tabelle farmaci di classe A e H al 19/01/2016

22 marzo 2016 – Il Presidente Melazzini visita il Policlinico Universitario Campus Bio-Medico di Roma

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multi-study analysis of response rates and safety

The PARP inhibitor olaparib (Lynparza™) demonstrates antitumor activity in women with relapsed ovarian cancer and a germline BRCA1/2 mutation (gBRCAm). Data from olaparib monotherapy trials were used to explore the treatment effect of olaparib in patients with gBRCAm ...
Leggi tutto

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain. This mutation is predicted to result in a substitution of cysteine by tyrosine at amino acid residue ...
Leggi tutto

Family Perspectives on Aggressive Cancer Care Near the End of Life

Patients with advanced-stage cancer are receiving increasingly aggressive medical care near death, despite growing concerns that this reflects poor-quality care. To assess the association of aggressive end-of-life care with bereaved family members’ perceptions of the ...
Leggi tutto

EGFR Mutations in Latinos From the United States and Latin America

Epidermal growth factor receptor (EGFR) mutations confer sensitivity to EGFR tyrosine kinase inhibitors in patients with advanced non–small-cell lung cancer (NSCLC). There are limited and conflicting reports on the frequency of EGFRmutations in Latinos. Samples from ...
Leggi tutto

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

Reports have suggested that metastatic site is an important predictor of overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), but these were based on a limited number of patients.We investigate the impact of site of metastases on OS ...
Leggi tutto

23 marzo 2016 – Il passo finale verso un mondo libero dalla polio

23 marzo 2016 – Nota Informativa Importante su idelalisib